1. Update 2009, Issue 4 With Permission from FDLI, www.fdli.orgPharmaceutical Patents in the Age of KSR by Patrick R. DelaneyTThe U.S. patent system is designed to promote…

Slide 1Michael D. Stein Principal Stein IP LLC 1400 Eye Street, NW Suite 300 Washington, DC 20005 (202) 216-9505 www.steinip.com [email protected] Nonobviousness Under 35…

Slide 1 Nonobviousness II: KSR: Requiem for the Suggestion Test Patent Law – Prof Merges 10.18.2011 Slide 2 Federal Circuit: Post-Graham 1.Elevation of “secondary”…

Slide 1 Nonobviousness II: Requiem for the Suggestion Test Patent Law – Prof Merges 3.11.08 Slide 2 [T]the differences between the subject matter sought to be patented…

USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. TC 1600 Biotech/Chem/Pharma Customer Partnership…

2011] 57 A SURPRISINGLY USEFUL REQUIREMENT Michael Risch* INTRODUCTION For 220 years, the Patent Act has required patentable inventions to be “new and useful.”1 For almost…